Sio Capital Management LLC Has $7.75 Million Position in Tyra Biosciences, Inc. $TYRA

Sio Capital Management LLC raised its position in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 94.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 810,274 shares of the company’s stock after purchasing an additional 393,657 shares during the quarter. Tyra Biosciences accounts for about 3.0% of Sio Capital Management LLC’s holdings, making the stock its 11th biggest holding. Sio Capital Management LLC owned about 1.53% of Tyra Biosciences worth $7,754,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. US Bancorp DE increased its stake in shares of Tyra Biosciences by 50.5% in the first quarter. US Bancorp DE now owns 5,435 shares of the company’s stock valued at $51,000 after buying an additional 1,823 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Tyra Biosciences during the 1st quarter worth approximately $84,000. Public Employees Retirement System of Ohio acquired a new position in Tyra Biosciences in the 2nd quarter valued at approximately $177,000. Intech Investment Management LLC raised its stake in shares of Tyra Biosciences by 46.5% during the second quarter. Intech Investment Management LLC now owns 19,919 shares of the company’s stock valued at $191,000 after acquiring an additional 6,322 shares during the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Tyra Biosciences by 5.8% during the first quarter. American Century Companies Inc. now owns 23,431 shares of the company’s stock worth $218,000 after purchasing an additional 1,289 shares during the period. 84.14% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on TYRA. Wedbush restated an “outperform” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Thursday, November 6th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Friday, August 22nd. Raymond James Financial began coverage on Tyra Biosciences in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating and a $35.00 price objective on the stock. Oppenheimer reiterated an “outperform” rating and issued a $36.00 target price on shares of Tyra Biosciences in a report on Wednesday, September 10th. Finally, Wall Street Zen lowered shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Tyra Biosciences Stock Performance

Tyra Biosciences stock opened at $20.81 on Tuesday. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -11.13 and a beta of 1.08. Tyra Biosciences, Inc. has a 52-week low of $6.42 and a 52-week high of $22.83. The stock’s 50 day moving average price is $15.60 and its two-hundred day moving average price is $12.44.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). On average, equities research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Insider Buying and Selling at Tyra Biosciences

In other news, Director Robert J. More sold 246,871 shares of the stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $20.25, for a total transaction of $4,999,137.75. Following the transaction, the director owned 3,833,425 shares of the company’s stock, valued at $77,626,856.25. This represents a 6.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 15.20% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.